Innovita Biological Technology Co., Ltd. (together with its subsidiaries, collectively known as “INNOVITA”,) is a biotechnology company focusing on the research, development, production and sales of in vitro diagnostic POCT products. It consists of Innovita (Beijing) , Innovita (Tangshan) and Innovita (Guangzhou).
● Founded in 2006
● On 28 July 2022 INNOVITA completed initial public offering and shares began trading on SSE STAR market
INNOVITA is a leading manufacturer of diagnostic solutions for healthcare, striving for a more efficient healthcare system to enhance the health and well-being of people all over the world.
INNOVITA has built six technical platforms such as antigen & antibody preparation, virus culture, colloidal gold, ELISA, fluorescence chromatography, immunofluorescence, and undertakes Chinese National High-tech R&D Program in the field of national major infectious diseases research and many other public health projects.
INNOVITA adheres to GMP Standards and owns 100,000 class clean rooms to ensure the safety and hygiene of our products.
We strictly implement ISO 13485 quality management system and follow the standards and regulations of EU, FDA, etc., to ensure that every product meets the requirements of our customers worldwide.